BMC public health · 2026
Feasibility study of a behavioral lifestyle intervention for Hispanic/Latino patients with metabolic dysfunction-associated steatotic liver disease.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Heredia Natalia I, Hwang Jessica P, Fernandez Maria E, Lu Jiachen, Bauer Cici X, McNeill Lorna H
Аннотация
INTRODUCTION: Metabolic dysfunction-associated steatotic liver disease (MASLD) can lead to longer-term adverse health outcomes if left unmanaged, including liver failure and liver cancer. Hispanic adults have the highest rates of MASLD of any U.S. racial/ethnic subgroup. The most effective treatment is weight loss, through healthy dietary changes and increased physical activity. This study conducted 2022-2023 aimed to assess the feasibility and acceptability (primary), as well as exploratory effectiveness outcomes, of a behavioral lifestyle intervention for Hispanic patients with MASLD.
METHODS: Participants were recruited from a federally qualified health center. Self-administered questionnaires assessed demographic, psychosocial and behavioral variables. Staff measured height and weight. Individuals were randomized into intervention or wait-list control groups. The intervention, Healthy Liver/Hígado Sano, is adapted from the Diabetes Prevention Program and involves 16 weekly, group-delivered sessions. We assessed feasibility and acceptability of delivering the program in partnership with a clinic, as well as summary statistics at baseline and follow-up. We calculated between-group differences in change between the two groups for exploratory effectiveness outcomes using two-sample t-tests and chi-square tests, as appropriate.
RESULTS: Of the 60 individuals screened, 45 were eligible (75%). Of these, 33 consented (73%) and 27 completed baseline data collection (60%) and were randomized, 13 to the wait-list control (usual care) and 14 to intervention condition. At follow-up, 19 of the 27 randomized (70%) were retained. Average age was 48.5 and 46.6 years in control and intervention groups, respectively. Most were female (84.6% control, 85.7% intervention) and had low acculturation (92-93%). Median satisfaction was 26 (of potential range 8-32), suggesting moderate acceptability among participants who completed follow-up. For exploratory effectiveness outcomes, while not statistically significant, intervention participants showed greater improvements in MASLD illness perception, treatment efficacy, social support, healthy eating index, and walking MET-minutes as compared to the control group.
CONCLUSIONS: Recruitment was feasible and participants found the intervention acceptable, though improvements are needed for retention. Findings will inform future trial implementation and refinement.
TRIAL REGISTRATION: This study was registered at clinicaltrials.gov (NCT05200585) on January 6, 2022.
METHODS: Participants were recruited from a federally qualified health center. Self-administered questionnaires assessed demographic, psychosocial and behavioral variables. Staff measured height and weight. Individuals were randomized into intervention or wait-list control groups. The intervention, Healthy Liver/Hígado Sano, is adapted from the Diabetes Prevention Program and involves 16 weekly, group-delivered sessions. We assessed feasibility and acceptability of delivering the program in partnership with a clinic, as well as summary statistics at baseline and follow-up. We calculated between-group differences in change between the two groups for exploratory effectiveness outcomes using two-sample t-tests and chi-square tests, as appropriate.
RESULTS: Of the 60 individuals screened, 45 were eligible (75%). Of these, 33 consented (73%) and 27 completed baseline data collection (60%) and were randomized, 13 to the wait-list control (usual care) and 14 to intervention condition. At follow-up, 19 of the 27 randomized (70%) were retained. Average age was 48.5 and 46.6 years in control and intervention groups, respectively. Most were female (84.6% control, 85.7% intervention) and had low acculturation (92-93%). Median satisfaction was 26 (of potential range 8-32), suggesting moderate acceptability among participants who completed follow-up. For exploratory effectiveness outcomes, while not statistically significant, intervention participants showed greater improvements in MASLD illness perception, treatment efficacy, social support, healthy eating index, and walking MET-minutes as compared to the control group.
CONCLUSIONS: Recruitment was feasible and participants found the intervention acceptable, though improvements are needed for retention. Findings will inform future trial implementation and refinement.
TRIAL REGISTRATION: This study was registered at clinicaltrials.gov (NCT05200585) on January 6, 2022.